PL1981858T3 - 3,5-di(arylo albo heteroarylo) izoksazole oraz 1,2,4-oksadiazole jako agoniści receptora S1P1, środki immunosupresyjne i przeciwzapalne - Google Patents
3,5-di(arylo albo heteroarylo) izoksazole oraz 1,2,4-oksadiazole jako agoniści receptora S1P1, środki immunosupresyjne i przeciwzapalneInfo
- Publication number
- PL1981858T3 PL1981858T3 PL07703028T PL07703028T PL1981858T3 PL 1981858 T3 PL1981858 T3 PL 1981858T3 PL 07703028 T PL07703028 T PL 07703028T PL 07703028 T PL07703028 T PL 07703028T PL 1981858 T3 PL1981858 T3 PL 1981858T3
- Authority
- PL
- Poland
- Prior art keywords
- immunosuppresssive
- isoxazoles
- oxadiazoles
- heteroaryl
- aryl
- Prior art date
Links
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 title 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000002545 isoxazoles Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0601744.6A GB0601744D0 (en) | 2006-01-27 | 2006-01-27 | Organic compounds |
| EP07703028A EP1981858B1 (en) | 2006-01-27 | 2007-01-25 | 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti-inflammatory agents |
| PCT/EP2007/000638 WO2007085451A2 (en) | 2006-01-27 | 2007-01-25 | 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL1981858T4 PL1981858T4 (pl) | 2010-12-31 |
| PL1981858T3 true PL1981858T3 (pl) | 2010-12-31 |
Family
ID=36061049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07703028T PL1981858T3 (pl) | 2006-01-27 | 2007-01-25 | 3,5-di(arylo albo heteroarylo) izoksazole oraz 1,2,4-oksadiazole jako agoniści receptora S1P1, środki immunosupresyjne i przeciwzapalne |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7799812B2 (pl) |
| EP (2) | EP1981858B1 (pl) |
| JP (1) | JP2009524611A (pl) |
| KR (1) | KR20080091161A (pl) |
| CN (1) | CN101374821A (pl) |
| AT (1) | ATE471313T1 (pl) |
| AU (1) | AU2007209533A1 (pl) |
| BR (1) | BRPI0707285A2 (pl) |
| CA (1) | CA2637081A1 (pl) |
| DE (1) | DE602007007186D1 (pl) |
| ES (1) | ES2347015T3 (pl) |
| GB (1) | GB0601744D0 (pl) |
| PL (1) | PL1981858T3 (pl) |
| PT (1) | PT1981858E (pl) |
| RU (1) | RU2008134534A (pl) |
| WO (1) | WO2007085451A2 (pl) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1546110A4 (en) | 2002-07-30 | 2008-03-26 | Univ Virginia | COMPOUNDS WITH EFFECT ON SIGNAL TRANSMISSION BY SPHINGOSINE-1-PHOSPHATE |
| US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| JP2008530135A (ja) | 2005-02-14 | 2008-08-07 | ユニバーシティ オブ バージニア パテント ファンデーション | アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト |
| HRP20110613T1 (hr) | 2005-03-23 | 2011-09-30 | Actelion Pharmaceuticals Ltd. | Hidrogenizirani derivati benzo[c] tiofena kao imunomodulatori |
| BRPI0612028A2 (pt) * | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| KR20080092385A (ko) | 2006-01-24 | 2008-10-15 | 액테리온 파마슈티칼 리미티드 | 신규한 피리딘 유도체 |
| EP1986623A2 (en) | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
| JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−１−リン酸受容体アナログ |
| MY149853A (en) | 2006-09-07 | 2013-10-31 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| AR062684A1 (es) | 2006-09-08 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos |
| JP5250556B2 (ja) | 2006-09-21 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | フェニル誘導体及びそれらの免疫調節薬としての使用 |
| NZ576893A (en) | 2006-11-21 | 2012-01-12 | Univ Virginia Patent Found | Tetralin analogs having sphingosine 1-phosphate agonist activity |
| WO2008064320A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| EP2097371A2 (en) | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
| AU2007334436A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| DK2125797T3 (da) * | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| US8324254B2 (en) * | 2007-04-19 | 2012-12-04 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists |
| HRP20110449T1 (hr) | 2007-08-17 | 2011-07-31 | Actelion Pharmaceuticals Ltd. | Derivati piridina kao modulatori receptora s1p1/edg1 |
| WO2009053481A1 (en) * | 2007-10-25 | 2009-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for modulating nk and t cell trafficking |
| ES2449749T3 (es) | 2007-11-01 | 2014-03-21 | Actelion Pharmaceuticals Ltd. | Nuevos derivados de pirimidina |
| ES2403209T3 (es) | 2007-12-10 | 2013-05-16 | Actelion Pharmaceuticals Ltd. | Derivados de tiofeno novedosos como agonistas de S1P1/EDG1 |
| WO2009082398A1 (en) | 2007-12-21 | 2009-07-02 | University Of Notre Dame Du Lac | Antibacterial compounds and methods of using same |
| US20110046170A1 (en) * | 2008-03-06 | 2011-02-24 | Martin Bolli | Novel pyrimidine-pyridine derivatives |
| CA2714665A1 (en) * | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Pyridine compounds |
| KR20100125380A (ko) | 2008-03-07 | 2010-11-30 | 액테리온 파마슈티칼 리미티드 | 신규한 아미노메틸 벤젠 유도체 |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| EP2210890A1 (en) * | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| EP2382212B1 (en) | 2009-01-23 | 2014-07-16 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| CN102361869A (zh) | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
| JP2012515789A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体 |
| KR101409131B1 (ko) | 2009-07-16 | 2014-06-17 | 액테리온 파마슈티칼 리미티드 | 피리딘-4-일 유도체 |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| SG182610A1 (en) | 2010-01-27 | 2012-08-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| US8273776B2 (en) * | 2010-04-16 | 2012-09-25 | Allergan, Inc | Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators |
| WO2011133734A1 (en) * | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| TW201206429A (en) * | 2010-07-08 | 2012-02-16 | Merck Serono Sa | Substituted oxadiazole derivatives |
| CN103124727B (zh) | 2010-07-20 | 2015-03-25 | 百时美施贵宝公司 | 取代的3-苯基-1,2,4-噁二唑化合物 |
| CN103237795B (zh) | 2010-09-24 | 2015-10-21 | 百时美施贵宝公司 | 经取代的噁二唑化合物及其作为s1p1激动剂的用途 |
| WO2012098505A1 (en) | 2011-01-19 | 2012-07-26 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
| EP2570404A1 (en) * | 2011-09-16 | 2013-03-20 | Syngenta Participations AG. | Plant growth regulating compounds |
| AU2013286860B2 (en) | 2012-07-02 | 2017-10-26 | Monsanto Technology Llc | Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
| JP2017533187A (ja) | 2014-09-25 | 2017-11-09 | ユニヴァーシティー オブ ノートル ダム デュ ラック | 非β−ラクタム系抗生物質 |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| EP3298008B1 (en) | 2015-05-20 | 2019-11-20 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| US11168062B2 (en) | 2016-09-12 | 2021-11-09 | University Of Notre Dame Du Lac | Compounds for the treatment of Clostridium difficile infection |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| US12364686B2 (en) | 2020-03-27 | 2025-07-22 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| CN111518091B (zh) * | 2020-04-22 | 2023-02-03 | 安徽医科大学 | 一种1，2，4-噁二唑并吡啶类化合物ahmu07及其作为抗菌药物的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000015213A1 (en) * | 1998-09-11 | 2000-03-23 | Shionogi & Co., Ltd. | Remedal or preventive agent for congestive heart failure |
| DE19904389A1 (de) * | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
| WO2001083464A1 (en) * | 2000-04-21 | 2001-11-08 | Shionogi & Co., Ltd. | Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders |
| CN1199956C (zh) * | 2000-04-21 | 2005-05-04 | 盐野义制药株式会社 | 具有抗癌作用的噁二唑衍生物 |
| PE20020544A1 (es) | 2000-11-07 | 2002-07-30 | Novartis Ag | Derivados de indolilmaleimida |
| WO2003000249A1 (en) * | 2001-06-26 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Function regulator for retinoid relative receptor |
| JP4219810B2 (ja) * | 2001-10-26 | 2009-02-04 | 塩野義製薬株式会社 | Ｍｍｐ阻害作用を有するスルホンアミド誘導体 |
| EP1491190A4 (en) | 2002-03-27 | 2006-01-04 | Shionogi & Co | DECOMPOSITION INHIBITOR FOR CARTRIDGE EXTRACELLULAR MATRIX |
| AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| US7365096B2 (en) | 2002-12-09 | 2008-04-29 | Board Of Regents, The University Of Texas System | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) |
| WO2004103279A2 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2004113330A1 (en) * | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
| WO2005012268A1 (ja) * | 2003-07-30 | 2005-02-10 | Shionogi & Co., Ltd. | イソオキサゾール環を有するスルホンアミド誘導体 |
| EP1670463A2 (en) | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| CN1894225A (zh) | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| GB2432834A (en) | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
| TW200538433A (en) * | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| BRPI0612028A2 (pt) * | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
-
2006
- 2006-01-27 GB GBGB0601744.6A patent/GB0601744D0/en not_active Ceased
-
2007
- 2007-01-25 EP EP07703028A patent/EP1981858B1/en not_active Not-in-force
- 2007-01-25 CA CA002637081A patent/CA2637081A1/en not_active Abandoned
- 2007-01-25 RU RU2008134534/04A patent/RU2008134534A/ru not_active Application Discontinuation
- 2007-01-25 BR BRPI0707285-6A patent/BRPI0707285A2/pt not_active IP Right Cessation
- 2007-01-25 ES ES07703028T patent/ES2347015T3/es active Active
- 2007-01-25 PT PT07703028T patent/PT1981858E/pt unknown
- 2007-01-25 JP JP2008551722A patent/JP2009524611A/ja active Pending
- 2007-01-25 KR KR1020087018321A patent/KR20080091161A/ko not_active Withdrawn
- 2007-01-25 EP EP10005624A patent/EP2233473A1/en not_active Withdrawn
- 2007-01-25 AT AT07703028T patent/ATE471313T1/de active
- 2007-01-25 AU AU2007209533A patent/AU2007209533A1/en not_active Abandoned
- 2007-01-25 US US12/162,413 patent/US7799812B2/en not_active Expired - Fee Related
- 2007-01-25 WO PCT/EP2007/000638 patent/WO2007085451A2/en not_active Ceased
- 2007-01-25 PL PL07703028T patent/PL1981858T3/pl unknown
- 2007-01-25 CN CNA2007800036158A patent/CN101374821A/zh active Pending
- 2007-01-25 DE DE602007007186T patent/DE602007007186D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US7799812B2 (en) | 2010-09-21 |
| WO2007085451A2 (en) | 2007-08-02 |
| EP1981858A2 (en) | 2008-10-22 |
| EP2233473A1 (en) | 2010-09-29 |
| AU2007209533A1 (en) | 2007-08-02 |
| JP2009524611A (ja) | 2009-07-02 |
| ATE471313T1 (de) | 2010-07-15 |
| PT1981858E (pt) | 2010-09-07 |
| BRPI0707285A2 (pt) | 2011-04-26 |
| PL1981858T4 (pl) | 2010-12-31 |
| EP1981858B1 (en) | 2010-06-16 |
| CA2637081A1 (en) | 2007-08-02 |
| WO2007085451A3 (en) | 2007-12-21 |
| CN101374821A (zh) | 2009-02-25 |
| ES2347015T3 (es) | 2010-10-22 |
| GB0601744D0 (en) | 2006-03-08 |
| US20090137636A1 (en) | 2009-05-28 |
| RU2008134534A (ru) | 2010-03-10 |
| KR20080091161A (ko) | 2008-10-09 |
| DE602007007186D1 (de) | 2010-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1981858T3 (pl) | 3,5-di(arylo albo heteroarylo) izoksazole oraz 1,2,4-oksadiazole jako agoniści receptora S1P1, środki immunosupresyjne i przeciwzapalne | |
| NO20085067L (no) | 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| WO2008051942A3 (en) | Farnesoid x receptor agonists | |
| WO2007076260A3 (en) | Farnesoid x receptor agonists | |
| WO2007028135A3 (en) | Imidazopyridine compounds | |
| NO20084783L (no) | Syntese av acylaminoalkenylenamider nyttige som substans P antagonister | |
| WO2009137391A3 (en) | Benzene sulfonamide thiazole and oxazole compounds | |
| WO2008013838A3 (en) | Pyridizinone derivatives | |
| ATE523514T1 (de) | Tricyclische triazolische verbindungen | |
| MX2010005109A (es) | Compuestos herbicidas. | |
| NO20083434L (no) | Benzamid- og heteroarenderivater | |
| WO2008070507A3 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| NO20092762L (no) | 2-aza-bicyklo[3.1.0]heksanderivater | |
| NO20092314L (no) | Benzamidderivater som EP4 receptoragonister | |
| NO20091626L (no) | MGLUR5-modulatorer | |
| NO20085107L (no) | Spirosykliske nitriler som proteaseinhibitorer | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| GB0411929D0 (en) | Organic compounds | |
| ATE496044T1 (de) | Indolylmaleimidderivate | |
| MX2009008221A (es) | Antagonista de receptor de cromeno s1p1. | |
| WO2009071691A3 (de) | Oxindol-derivate und ihre verwendung als medikament | |
| WO2009021957A3 (en) | Tricyclic heterocyclic compounds as gaba a modulators | |
| WO2007048841A3 (de) | Neue indol-haltige beta-agonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
| WO2008064829A3 (en) | Novel aminothienopyridinone derivatives processes for preparing them and pharmaceutical compositions thereof |